Viking Therapeutics, Inc - VKTX STOCK NEWS

Viking Therapeutics has initiated a Phase 2 clinical trial of VK2735, a dual agonist of GLP-1 and GIP receptors, for the potential treatment of metabolic disorders such as obesity. The 13-week trial will evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of four different doses of VK2735. The primary endpoint is the percent change in body weight from baseline to Week 13.

Viking Therapeutics, Inc. will release its financial results for the second quarter of 2023 on July 26. The company, focused on developing therapies for metabolic and endocrine disorders, will host a conference call at 4:30 p.m. Eastern Time to discuss the results and general corporate updates. A telephone replay will be available until August 2, and the conference call can also be accessed live via the internet.

Viking Therapeutics announces positive results from Phase 2b clinical trial of VK2809 in patients with NASH, achieving significant reductions in liver fat and plasma lipids. The drug demonstrates impressive potency and excellent safety and tolerability.

Viking Therapeutics (NASDAQ: VKTX) reported its Q1 2023 financial results on April 26, 2023, highlighting significant developments in its clinical pipeline. The company completed enrollment in the Phase 2b VOYAGE study of VK2809 for NASH and fibrosis, with data expected in Q2 2023. Viking also announced Phase 1 results for VK2735, showcasing up to 6% placebo-adjusted weight loss and a strong safety profile. The initiation of a Phase 1 trial for an oral formulation of VK2735 was also noted. Financially, Viking completed a public offering raising $287.5 million, enhancing its cash position to approximately $406 million. However, the net loss for the quarter increased to $19.5 million, or $0.25 per share, compared to a loss of $16.1 million, or $0.21 per share in 2022.

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, will release its financial results for the first quarter of 2023 on April 26, 2023, post-market close. A conference call to discuss the results and corporate updates is scheduled for 4:30 p.m. Eastern Time on the same day. Investors can participate by dialing (844) 850-0543 within the U.S. or (412) 317-5199 internationally. The call will also be available via live webcast and can be replayed until May 3, 2023. Viking Therapeutics focuses on developing therapies for metabolic and endocrine disorders and has three compounds in clinical trials, including VK2809, which is in a Phase 2b study for treating non-alcoholic steatohepatitis.

On April 11, 2023, Viking Therapeutics (NASDAQ: VKTX) announced that its CEO, Brian Lian, Ph.D., will present at the 22nd Annual Needham Healthcare Conference. The conference is scheduled for April 17-20, 2023, with Viking's presentation set for 10:15 a.m. Eastern on April 18, 2023. This virtual event will feature corporate presentations and one-on-one meetings between management and investors.

Viking Therapeutics specializes in developing novel therapies for metabolic and endocrine disorders, with three compounds under clinical trials. Notable projects include VK2809, targeting non-alcoholic steatohepatitis (NASH) and VK2735, aimed at metabolic disorders. The company’s expertise in metabolism drives its innovative therapeutic approach.

Viking Therapeutics (Nasdaq: VKTX) announced the closing of a public offering of 19,828,300 shares of common stock at $14.50 per share, generating gross proceeds of approximately $287.5 million. The underwriters exercised their option to purchase an additional 2,586,300 shares. Proceeds will fund the continued development of VK2809, VK2735, and VK0214 programs, alongside general research and development. The offering was conducted under an effective shelf registration statement filed with the SEC. Notably, Viking's clinical programs target metabolic and endocrine disorders, with promising developments in treatments for NASH and X-ALD.